Assertio Holdings Inc
NASDAQ:ASRT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Assertio Holdings Inc
NASDAQ:ASRT
|
US |
|
Shun Ho Holdings Ltd
HKEX:253
|
HK |
|
F
|
Fore Kopi Indonesia PT Tbk
IDX:FORE
|
ID |
|
S
|
Singapore Airlines Ltd
SWB:SIA1
|
SG |
|
B
|
Bhagwan Marine Ltd
ASX:BWN
|
AU |
|
S
|
Suzhou Maxwell Technologies Co Ltd
SZSE:300751
|
CN |
Assertio Holdings Inc
Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
Rolvedon focus: Management says Rolvedon is the core growth engine — integration is complete and newly labeled commercial sales are expected to begin in Q2 2026 with material upside vs. 2025.
2026 outlook: Company initiated fiscal 2026 guidance of $110 million to $125 million in revenue and $28 million to $40 million in adjusted EBITDA.
Shift in BD strategy: Assertio will prioritize oncology therapeutics (on-market or late‑stage) that leverage its community oncology commercial footprint and be more selective on acquisitions.
Q4 receipts and cash dynamics: Q4 product sales were $12.8 million (down vs. prior year) and cash decreased to $63.4 million as of Dec 31, 2025, driven by temporary working capital tied to the Rolvedon sell‑in; management expects normalization by end of April.
Cost structure gains: Q4 SG&A fell to $13.1 million after restructuring and lower litigation expense; full‑year adjusted EBITDA rose to $22.7 million partly from lower SG&A and better gross margin.
Tail assets and Indocin: Indocin remains a declining tail product amid expected additional generic competition in 2026; management expects ongoing erosion but will try to maximize profitability.
Commercial capability: Management highlights a scalable, community oncology‑focused commercial platform (field sales, national accounts, hub/reimbursement) that can support additional oncology products.
